PT003 MDI Cardiovascular Safety Study

PHASE2CompletedINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

PT005 MDI

PT005 MDI administered as two puffs BID for 14 days

DRUG

PT001 MDI

PT001 MDI administered as two puffs BID for 14 days

DRUG

PT003 MDI

PT003 MDI administered as two puffs BID for 14 days

DRUG

Formoterol Fumarate 12 μg (Foradil® Aerolizer®)

Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days

Trial Locations (20)

Unknown

Pearl Investigative Site, Glendale

Pearl Investigative Site, Fullerton

Pearl Investigative Site, Los Angeles

Pearl Investigative Site, San Diego

Pearl Investigative Site, Pensacola

Pearl Investigative Site, Lafayette

Pearl Investigative Site, North Dartmouth

Pearl Investigative Site, Livonia

Pearl Investigative Site, Medford

Pearl Investigative Site, San Antonio

Pearl Investigative Site, Glebe

Pearl Investigative Site, Caboolture

Pearl Investigative Site, Dawpark

Pearl Investigative Site, Toorak Gardens

Pearl Investigative Site, Heidelberg

Pearl Investigative Site, Nedlands

Pearl Investigative Site, Caversham

Pearl Investigative Site, Private Bag

Pearl Investigative Site, Tauranga

Pearl Investigative Site, Newtown

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY